BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

Doer Biologics Initiates Phase I MAD Trial of DR10624, Receives NMPA IND Approval

The Phase I MAD study is a randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics ...

August 02, 2023 | News

Chinese Patent Granted for CytoMed Therapeutics' Allogeneic CAR-Gamma Delta T Cell Technology

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its propr...

August 02, 2023 | News

Indonesia-China Healthcare and Biotech Investment Forum Explores Collaborative Opportunities

The forum was chaired by Mr. Jafar WANG, Co-Chief Investment Officer of Legend Capital, who mentioned Legend Capital's latest "Ecosystem plus" strategy in ...

August 01, 2023 | News

NMPA and FDA Approve First-in-Human Trial for LBL-034 in Multiple Myeloma

This is a first-in-human, single-arm, multicenter, open-label, dose-escalation and expansion clinical study, and plans to enroll patients with relapsed/ref...

August 01, 2023 | News

Daewoong Pharmaceutical Seeks Approval for Fexuprazan in China's Anti-Ulcer Drug Market

Daewoong Pharmaceutical's domestically produced drug no. 34 Fexuprazan, a newly developed one for the treatment of gastroesophageal reflux disease (GERD), ...

July 31, 2023 | News

Transcenta's Anti-sclerostin Antibody TST002 Approved for Phase II Trial in China for Reduced Bone Density Patients

This study aims to evaluate the safety, tolerability, and pharmacokinetics of TST002(Blosozumab) after single and multiple intravenous administrations in p...

July 31, 2023 | News

Recbio's Novel Adjuvanted Shingles Vaccine Receives Clinical Trial Approval in China and Progresses Overseas

The Company proposes to adopt a randomized, double-blind, Shingrix® parallel controlled phase I clinical trial in 180 healthy adult subjects aged 40 an...

July 27, 2023 | News

China's Mabwell Announces NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND

B7-H3 is a member of the B7 ligand family and is overexpressed in most cancer types but expressed at a low level in normal tissues. In malignant tissues, B...

July 24, 2023 | News

Lynk Pharmaceuticals Doses First Atopic Dermatitis Patient with LNK01004 in Phase Ib Study

The trial was designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of LNK01004 ointment in Chinese patie...

July 21, 2023 | News

BioCity Initiates Phase 1 Trial with CDH3-Targeting ADC BC3195, First Patient Dosed

The study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of BC3195 in patients with locally advanced or metastatic solid ...

July 20, 2023 | News

Biotheus Partners with BioNTech in Global Research Collaboration & License Deal

Under the terms of the agreement, Biotheus will grant BioNTech worldwide, exclusive options to a preclinical-stage bispecific antibody and a clinical-stage...

July 20, 2023 | News

Mabwell Announces the NMPA Approval of Novel Trop-2 ADC (9MW2921) for IND

9MW2921 is a next generation antibody-drug conjugate (ADC) developed by Mabwell based on IDDC™ (Interchain-Disulfide Drug Conjugate) platef...

July 19, 2023 | News

Duoning Biotech Acquires PreFluid to Strengthen Fluid Management Solutions

PreFluid is a leader in integrated fluid solutionsPreFluid's peristaltic pumps are widely used in medical, pharmaceutical, chemical and environmental indus...

July 19, 2023 | News

Sartorius completes acquisition of Polyplus

Polyplus is a leading provider of innovative technologies for cell and gene therapies. Transfection reagents developed and produced by Polyplus are key com...

July 18, 2023 | News

Stay Connected